Wise G R, Schultz T T
Division of General Internal Medicine and Geriatric Medicine, Loma Linda University Medical Center, CA 92350, USA.
Postgrad Med. 1996 Jul;100(1):138-49. doi: 10.3810/pgm.1996.07.13.
A high serum cholesterol level is regarded as a major contributor to the development of coronary atherosclerosis. Screening for hyperlipidemia should begin no later than age 35 for men and age 45 for women. Individuals with additional risk factors for coronary artery disease should be screened earlier. When values are not within a desirable range, further assessment should be done by determining high-density lipoprotein and triglyceride levels. The initial approach to treatment of hyperlipidemia includes diet, exercise, and weight loss. Smoking should be proscribed. When nonpharmacologic intervention fails, "statins" are increasingly being selected as agents of first choice. Recommendations for the busy practitioner include consistently identifying the hyperlipidemic patient, setting target goals for lipid values, addressing modifiable risk factors, and providing appropriate pharmacologic intervention (eg, aspirin, antioxidants, and beta blockers in patients with established disease; angiotensin-converting enzyme inhibitors in patients with systolic dysfunction; estrogen replacement in selected patients) and treatment to attain target goals in lowering cholesterol.
高血清胆固醇水平被视为冠状动脉粥样硬化发展的主要促成因素。男性高脂血症筛查应在35岁之前开始,女性应在45岁之前开始。有冠状动脉疾病其他危险因素的个体应更早进行筛查。当数值不在理想范围内时,应通过测定高密度脂蛋白和甘油三酯水平进行进一步评估。高脂血症的初始治疗方法包括饮食、运动和减肥。应禁止吸烟。当非药物干预失败时,“他汀类药物”越来越多地被选作首选药物。对于忙碌的从业者的建议包括持续识别高脂血症患者、设定血脂值的目标、处理可改变的危险因素、提供适当的药物干预(例如,对已确诊疾病的患者使用阿司匹林、抗氧化剂和β受体阻滞剂;对收缩功能障碍患者使用血管紧张素转换酶抑制剂;对选定患者进行雌激素替代)以及进行治疗以实现降低胆固醇的目标。